DA
ISEE

Denali Advisors’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Denali Advisors’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,100
Closed -$35K – 426
2021
Q4 		$35K Buy
+2,100
New +$34.4K 0.01% 284

Other funds holding ISEE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $291M AUM 19.43% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Denali Advisors's ISEE Position: Q1 2022 in Review

Denali Advisors sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q1 2022, closing a stake of 2,100 shares — an estimated $35K sold.

Denali Advisors first reported a position in ISEE in Q4 2021 and held it in 1 quarter. The position peaked at $35K in Q4 2021. 163 funds tracked by Wall St. Rank hold ISEE as of Q1 2022.

  • Denali Advisors reported no remaining IVERIC bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Denali Advisors sold 2,100 IVERIC bio, Inc. Common Stock shares in Q1 2022, an estimated $35K.
  • Denali Advisors first reported a position in IVERIC bio, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Denali Advisors's IVERIC bio, Inc. Common Stock position peaked at $35K in Q4 2021.
  • 163 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q1 2022.

Based on Denali Advisors's 13F filing for Q1 2022, filed 19 Apr 2022.